NovoCure Q3 2024 GAAP EPS $(0.28) Beats $(0.33) Estimate, Sales $155.09M Beat $143.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
NovoCure reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.28), beating the estimate of $(0.33), and sales of $155.09M, surpassing the $143.95M estimate. Sales increased by 21.81% compared to the same period last year.
October 30, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NovoCure's Q3 2024 results exceeded expectations with a GAAP EPS of $(0.28) and sales of $155.09M, both beating analyst estimates. Sales grew by 21.81% year-over-year.
NovoCure's better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. The significant year-over-year sales growth further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100